BioNTech SE

BioNTech is a German biotechnology company pioneering mRNA-based immunotherapies and precision medicines. Founded in 2008 by scientists Uğur Şahin, Özlem Türeci, and Christoph Huber, BioNTech gained worldwide recognition for co-developing the first mRNA-based COVID-19 vaccine (Comirnaty) with Pfizer. The company’s research spans oncology, infectious diseases, and rare diseases, leveraging its proprietary mRNA and cell therapy platforms.

Mission and Vision

Mission: To harness the power of the immune system to fight cancer and infectious diseases through cutting-edge science and innovation.
Vision: To become a global leader in next-generation immunotherapies, revolutionizing healthcare with mRNA and personalized medicine.

Products and Services

Approved Product:
- Comirnaty® (BNT162b2): The world’s first authorized mRNA COVID-19 vaccine, developed in partnership with Pfizer.
Pipeline Programs:
- Oncology: mRNA cancer vaccines, individualized neoantigen therapies (iNeST), bispecific antibodies, and cell therapies.
- Infectious Diseases: Next-gen mRNA vaccines targeting influenza, shingles, tuberculosis, malaria, and HIV.
- Rare Diseases: mRNA-based treatments for genetic disorders.
Technology Platforms: Proprietary mRNA platforms, CAR-T cell therapy, antibodies, and protein engineering.

Growth and Innovation
BioNTech’s success with Comirnaty placed it at the forefront of biotechnology, proving the viability of mRNA technology on a global scale. The company reinvests its vaccine revenues into expanding its pipeline, particularly in oncology and next-gen vaccines. It collaborates with major partners including Pfizer, Genmab, Regeneron, and Roche’s Genentech. BioNTech is also building manufacturing hubs in Africa to support vaccine equity.

Global Impact
With operations in Europe, North America, and Asia, BioNTech has transformed the landscape of global health. Its COVID-19 vaccine has saved millions of lives and set the foundation for future pandemic preparedness. In oncology, BioNTech aims to bring personalized cancer vaccines to patients worldwide, advancing the frontier of precision medicine.